Centessa Pharmaceuticals plc

CIK: 1847903 Filed: June 24, 2026 8-K Acquisition High Impact

Key Highlights

Successful acquisition of Centessa Pharmaceuticals by Eli Lilly
Shareholders receive $38.00 per share in cash
Potential for additional $9.00 per share via Contingent Value Rights (CVRs)
Centessa transitions to a wholly owned subsidiary of Eli Lilly

Event Analysis

Centessa Pharmaceuticals plc: Acquisition Update

On June 24, 2026, Eli Lilly and Company finalized its acquisition of Centessa Pharmaceuticals plc. Centessa is now a wholly owned subsidiary of Eli Lilly. As a result, Centessa’s American Depositary Shares (ADSs), which traded on the Nasdaq under the ticker "CNTA," have stopped trading and the company has delisted from the exchange.

1. What happened?

The merger process is complete. Centessa is no longer an independent, publicly traded company. All outstanding Centessa shares have been converted into the right to receive a cash payment and potential future value through Contingent Value Rights (CVRs).

2. What does this mean for shareholders?

If you held shares on June 23, 2026, you are entitled to the following:

Cash Payment: You receive $38.00 per share in cash, minus any applicable taxes. This payment does not accrue interest.
Contingent Value Rights (CVRs): You received one non-transferable CVR for every share you owned. These rights could pay out up to $9.00 per share, but only if Centessa’s drug programs hit specific development and regulatory milestones. The company has not provided a detailed timeline for these milestones, so these should be viewed as a potential "bonus" rather than a guaranteed payout.

3. Why does this matter for your portfolio?

Centessa is no longer a public company. You can no longer trade "CNTA" shares because the stock no longer exists. Because the company is delisted from the Nasdaq, it is no longer required to file public reports with the Securities and Exchange Commission (SEC). Eli Lilly now manages all company operations and oversight.

4. What should you do now?

Check your brokerage account: You should see the $38.00 per share cash payment in your account. If the funds are missing, contact your broker immediately to confirm the status of your payment.
Track CVR milestones: Your CVRs are held in "book-entry" form. You do not need to take any action right now. However, keep an eye on official communications from Eli Lilly regarding the clinical and regulatory goals mentioned in the original merger agreement. Future payouts depend entirely on hitting those specific targets.
Update your records: Since "CNTA" is no longer a tradable asset, remove it from your active watchlists or portfolio trackers to avoid confusion.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be taken as professional investment advice. Always consult with a qualified financial advisor regarding your specific tax and investment situation.

Key Takeaways

CNTA stock is no longer tradable; remove from watchlists immediately
Cash payments should be verified in brokerage accounts; contact brokers if missing
CVRs are held in book-entry form and require no immediate action
Monitor Eli Lilly communications for updates on clinical milestones linked to CVRs

Why This Matters

This acquisition marks the definitive exit of Centessa Pharmaceuticals plc from the public markets, signaling a broader trend of consolidation within the pharmaceutical sector. For investors, this transition from active equity to a cash-plus-CVR (Contingent Value Right) structure represents a fundamental shift from market-driven valuation to milestone-driven performance. You are no longer betting on the daily fluctuations of the Nasdaq; instead, your remaining potential upside is tethered strictly to the clinical or regulatory success of specific assets, which are often non-guaranteed and carry significant execution risk. This event is part of a wider wave of industry M&A activity that has reshaped the biotech landscape throughout the second quarter of 2026. We have seen a rapid succession of similar exits, including the acquisition of KalVista Pharmaceuticals, Inc. by Chiesi Group, the merger of Assertio Holdings, Inc. with Zydus Lifesciences, and the buyout of Kezar Life Sciences, Inc. by Aurinia Pharmaceuticals Inc. Furthermore, the $5.3 billion acquisition of Apellis Pharmaceuticals, Inc. by Biogen and the $124.00 per share cash deal for Nuvalent, Inc. by GlaxoSmithKline (GSK) underscore a high-premium environment for clinical-stage innovators. Even companies like Rallybio Corp have opted for fundamental transformations through reverse mergers to survive. For the retail investor, this cluster of activity serves as a critical reminder to audit your portfolios immediately. When a company like Centessa Pharmaceuticals plc is delisted, your brokerage account will eventually reflect the cash consideration, but you must proactively track the CVRs, which often require specific corporate actions or monitoring to realize value. Do not assume your broker will manage the long-term tracking of these complex instruments. Ensure you have documented the specific milestones tied to your CVRs, as these are the only remaining levers for potential profit now that the primary equity has been extinguished. In this high-velocity M&A environment, passive holding is no longer a viable strategy; active oversight is required to capture the full value of your exit proceeds.

Financial Impact

Shareholders receive $38.00 cash per share plus potential CVRs worth up to $9.00 per share based on future milestones.

Affected Stakeholders

Investors

Employees

Regulators

Learn More

How to Read an 8-K Filing

Understanding material event disclosures

Understanding SEC Filings & CIK

How to navigate SEC filings

About This Analysis

AI-powered summary derived from the original SEC filing.

How we analyze filings → | About Stockadora →

Document Information

Event Date: June 24, 2026

Processed: June 25, 2026 at 02:52 AM

View Original SEC Filing

AI-Generated Analysis

This analysis is AI-generated from SEC filings. This is educational content, not financial advice. Always consult a financial advisor before making investment decisions.

Back to All Events